



AYSA

THERAPEUTICS INFUSION

PULMONARY ORDER FORM

P: 470.395.6076 | F: 470.745.0716

PATIENT INFORMATION

Demographics attached

Patient Name: _____ DOB: _____ Phone: _____

INSURANCE INFORMATION: PLEASE ATTACH COPY OF PRESCRIPTION/MEDICAL CARD(S) (FRONT AND BACK)

MEDICAL INFORMATION

Patient Weight: _____ lbs. Allergies: _____

Clinical/Progress Notes, Labs, and Tests supporting primary diagnosis attached

Labs: Required labs to be drawn by: Infusion Clinic Referring Physician

Lab Orders: _____

FASENRA INJECTION

Severe Asthma with Eosinophilic phenotype (ICD-10 _____)

Fasenra Initial Dose: 30mg subcutaneously every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter

Fasenra Maintenance Dose: 30mg subcutaneously every 8 weeks

XOLAIR INJECTION

Allergic Asthma (ICD-10: _____) _____

Xolair Dose: 150mg 225mg 300mg 375mg Frequency: Subcutaneously every: 2 weeks or 4 weeks

History: Positive Skin or RAST Test: Yes No Test date: _____

Pre-Treatment IgE Serum: _____ IU/mL Test date: _____

** Date of last Xolair Injection: _____ Note: Patient must have an EpiPen in their possession at every appointment.

PROLASTIN INJECTION

Alpha-1 Antitrypsin Deficiency (ICD-10 _____) Panacinar Emphysema (ICD-10 _____)

Prolastin Dose: 60mg/kg IV weekly OR Other: _____

Premedication: _____

** Date of last Prolastin Infusion: _____

GLASSIA INJECTION

Alpha-1 Antitrypsin Deficiency (ICD-10 _____)

Glassia Dose: 60mg/kg IV weekly OR Other: _____

** Date of last Glassia Infusion: _____

ADDITIONAL ORDERS/COMMENTS

PHYSICIAN INFORMATION

By signing this form and utilizing our services, you are authorizing *At Your Service Anesthesia, Inc.*, and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies.

Physician Signature: _____ Physician Name: _____ Date: _____

Phone: _____ Fax: _____ Contact Person: _____

ATYOURSERVICEANESTHESIA.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately. If you have received this in error, destroy the document immediately.